Effects of cannabinoids on caffeine contractures in slow and fast skeletal muscle fibers of the frog.
The effect of cannabinoids on caffeine contractures was investigated in slow and fast skeletal muscle fibers using isometric tension recording. In slow muscle fibers, WIN 55,212-2 (10 and 5 microM) caused a decrease in tension. These doses reduced maximum tension to 67.43 +/- 8.07% (P = 0.02, n = 5) and 79.4 +/- 14.11% (P = 0.007, n = 5) compared to control, respectively. Tension-time integral was reduced to 58.37 +/- 7.17% and 75.10 +/- 3.60% (P = 0.002, n = 5), respectively. Using the CB(1) cannabinoid receptor agonist ACPA (1 microM) reduced the maximum tension of caffeine contractures by 68.70 +/- 11.63% (P = 0.01, n = 5); tension-time integral was reduced by 66.82 +/- 6.89% (P = 0.02, n = 5) compared to controls. When the CB(1) receptor antagonist AM281 was coapplied with ACPA, it reversed the effect of ACPA on caffeine-evoked tension. In slow and fast muscle fibers incubated with the pertussis toxin, ACPA had no effect on tension evoked by caffeine. In fast muscle fibers, ACPA (1 microM) also decreased tension; the maximum tension was reduced by 56.48 +/- 3.4% (P = 0.001, n = 4), and tension-time integral was reduced by 57.81 +/- 2.6% (P = 0.006, n = 4). This ACPA effect was not statistically significant with respect to the reduction in tension in slow muscle fibers. Moreover, we detected the presence of mRNA for the cannabinoid CB(1) receptor on fast and slow skeletal muscle fibers, which was significantly higher in fast compared to slow muscle fiber expression. In conclusion, our results suggest that in the slow and fast muscle fibers of the frog cannabinoids diminish caffeine-evoked tension through a receptor-mediated mechanism.
Huerta
Miguel
M
Unidad de Investigación Dr. Enrico Stefani del, Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Colonia Villa San Sebastián, Colima, México.
Ortiz-Mesina
Mónica
M
Trujillo
Xóchitl
X
Sánchez-Pastor
Enrique
E
Vásquez
Clemente
C
Castro
Elena
E
Velasco
Raymundo
R
Montoya-Pérez
Rocío
R
Onetti
Carlos
C
D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology*; D002186:Cannabinoids / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D009025:Morpholines / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects*; D018656:Muscle Fibers, Fast-Twitch / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D018485:Muscle Fibers, Skeletal / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology*; D018657:Muscle Fibers, Slow-Twitch / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D011720:Pyrazoles / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics; D011894:Rana pipiens; D043884:Receptor, Cannabinoid, CB1 / Q000819:agonists / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction
D001095:Arachidonic Acids; D002186:Cannabinoids; D000697:Central Nervous System Stimulants; D009025:Morpholines; D011720:Pyrazoles; D012333:RNA, Messenger; D043884:Receptor, Cannabinoid, CB1; C119324:arachidonylcyclopropylamide; D002110:Caffeine; C109925:AM 281